eldisine 5 mg inj. sol. (pwdr.) i.v. vial
eg sa-nv - vindesine sulfate 5 mg - powder for solution for injection - 5 mg - vindesine sulfate 5 mg - vindesine
eldisine
eli lilly and company (nz) limited - vindesine sulfate 5mg; - powder for injection - 5 mg - active: vindesine sulfate 5mg
eldisine 5mg powder for solution for injection vials
genus pharmaceuticals ltd - vindesine sulfate - powder for solution for injection - 5mg
eldisine vindesine sulfate 5mg powder for injection vial
aspen pharmacare australia pty ltd - vindesine sulfate, quantity: 5 mg - injection, powder for - excipient ingredients: mannitol - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) eldisine is indicated in the palliative treatment of the following: acute lymphocytic leukaemia of childhood resistant to other agents. blastic crises of chronic myeloid leukaemia in adults. non-small cell lung cancer. it should be noted that eldisine is usually given in combination with other oncolytic agents.
eldisine inj 5mg/2ml powder for solution
eli lilly canada inc - vindesine sulfate - powder for solution - 5mg - vindesine sulfate 5mg - antineoplastic agents
dbl vincristine sulfate 2mg/2ml injection vial
pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma
dbl vincristine sulfate 1mg/1ml injection vial
pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma
vincristine sulfate injection
vincristine sulfate -
pfizer (australia) vincristine sulfate 2mg/2ml injection vial
pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder
fildesin injection 1mg (注射用フィルデシン1mg)
nichi-iko pharmaceutical co.,ltd - vindesine sulfate - injection